R-Tech Ueno Discloses Results Of Phase 2 Retinitis Pigmentosa Clinical Trial
Sucampo Pharmaceuticals, Inc. has confirmed that its partner, R-Tech Ueno, Ltd. (”RTU”) has reported the results of its recently completed phase 2 clinical trial of UF-021 in retinitis pigmentosa patients. The results showed improvement in visual function dose-dependently in both visual field test and subjective findings. Furthermore, although there was an irritation upon instillation, there were no severe adverse effects.
Read the full story here




A tiny glass telescope of the size of a pea has been successfully implanted in the eyes of people with severely damaged retinas, helping them to read and watch television. The new device by VisionCare Ophthalmic Technologies is for people with an irreversible, advanced form of macular degeneration in which a blind spot develops in the central vision of both eyes. The device, which has received unanimous recommendation from the FDA advisory panel, may receive FDA approval by the end of the year.
Researchers at EyeVis Eye and Vision Research Institute have reported positive results from the first year clinical trial. The trial is testing whether specialized contact lenses in the non-surgical overnight corneal reshaping process can slow or halt the progression of near sightedness in children. The specially designed contact lenses, when worn overnight in sleep, can change the shape of the cornea. The induced flatter curvature of the cornea results in clear vision, reducing or eliminating the dependence on contact lenses or glasses during waking hours.
arGentis Pharmaceuticals LLCannounced that the company has licensed a third treatment for Dry Eye Syndrome (DES) now designated ARG103. This is a continuance of arGentis’ licensing partnership with the Southern College of Optometry (SCO) and ARG103 becomes the third prospective therapy for DES that utilizes the transdermal delivery of an active pharmaceutical ingredient to affected glands via application of a cream or gel to the outer, upper and lower eyelids. ARG103 will broaden the reach of arGentis’ transdermal ocular technology, which includes ARG101 for use in menopausal women and ARG102, a progesterone-based formulation that treats DES in younger women and men.